The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Characterization of novel potent and selective anaplastic lymphoma kinase (ALK) inhibitors.
C. M. Lovly
No relevant relationships to disclose
E. de Stanchina
No relevant relationships to disclose
H. Chen
No relevant relationships to disclose
C. Liang
Employment or Leadership Position - Xcovery
Stock Ownership - Xcovery
W. Pao
Research Funding - Xcovery